Stephanie Lheureux

Stephanie Lheureux

UNVERIFIED PROFILE

Are you Stephanie Lheureux?   Register this Author

Register author
Stephanie Lheureux

Stephanie Lheureux

Publications by authors named "Stephanie Lheureux"

Are you Stephanie Lheureux?   Register this Author

60Publications

1522Reads

36Profile Views

DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer.

Clin Cancer Res 2019 Oct 23;25(19):5729-5731. Epub 2019 Jul 23.

Princess Margaret Cancer Centre, University Health Network. Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1797DOI Listing
October 2019

The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.

J Clin Oncol 2019 Sep 12;37(27):2449-2459. Epub 2019 Aug 12.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00347DOI Listing
September 2019

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

CA Cancer J Clin 2019 Jul 17;69(4):280-304. Epub 2019 May 17.

Chief, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit; and Director, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network and Mt. Sinai Health System, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21559DOI Listing
July 2019

Tailoring Ovarian Cancer Treatment: Implications of Mutations.

Cancers (Basel) 2019 Mar 23;11(3). Epub 2019 Mar 23.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Center, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468364PMC
March 2019

Epithelial ovarian cancer.

Lancet 2019 Mar;393(10177):1240-1253

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)32552-2DOI Listing
March 2019

Rucaparib: a novel PARP inhibitor for advanced ovarian cancer.

Drug Des Devel Ther 2018 21;12:605-617. Epub 2018 Mar 21.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S130809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868608PMC
October 2018

The role of niraparib for the treatment of ovarian cancer.

Future Oncol 2018 Oct 1;14(25):2565-2577. Epub 2018 Jun 1.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre & Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0101DOI Listing
October 2018

Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?

Clin Cancer Res 2018 07 26;24(14):3233-3235. Epub 2018 Mar 26.

Princess Margaret Cancer Centre, Medical Oncology - Drug Development Program, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0380DOI Listing
July 2018

Emerging growth factor receptor antagonists for ovarian cancer treatment.

Expert Opin Emerg Drugs 2018 03 12;23(1):1-16. Epub 2018 Mar 12.

a Princess Margaret Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1446942DOI Listing
March 2018

Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.

Methods 2017 11 23;130:23-35. Epub 2017 Jul 23.

Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2017.07.018DOI Listing
November 2017

Resisting RECIST-Uniformity Versus Clinical Validity.

Int J Gynecol Cancer 2017 10;27(8):1619-1627

*Auckland City Hospital, Auckland, New Zealand; †Prince of Wales Hospital, Sydney, Australia; ‡Princess Margaret Cancer Centre, Toronto, Ontario Canada; §Department of Radiation Oncology, Loyol University, Chicago, IL; ‖Instituto Valenciano de Oncologia, Valencia, Spain; ¶Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Paris, France; and #Gynecologic Group Intergroup, Kingston, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001062DOI Listing
October 2017

Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.

Expert Opin Biol Ther 2017 08 22;17(8):927-943. Epub 2017 Jun 22.

a Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1340935DOI Listing
August 2017

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

J Clin Oncol 2017 Jul 11;35(20):2329-2337. Epub 2017 Apr 11.

Goli Samimi, Charlisse F. Caga-anan, Michael Dean, Leah E. Mechanic, Lori M. Minasian, and Mark E. Sherman, National Cancer Institute; Lawrence C. Brody, National Human Genome Research Institute, Bethesda, MD; Marcus Q. Bernardini, Stephanie Lheureux, Patricia A. Shaw, Princess Margaret Cancer Centre, Toronto, Ontario; Janice S. Kwon, University of British Columbia; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Ian G. Campbell, Paul A. James, Masataka Takenaka, and David D. Bowtell, Peter MacCallum Cancer Centre; David D. Bowtell, University of Melbourne, Melbourne, Victoria; Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Brisbane, Queensland; Michael Friedlander, The Prince of Wales Hospital; Susan J. Ramus, University of New South Wales; Susan J. Ramus and David D. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; Fergus J. Couch, Mayo Clinic, Rochester, MN; Joanne A. de Hullu and Marline G. Harmsen, Radboud University Medical Center, Nijmegen, the Netherlands; Susan M. Domchek and Ronny Drapkin, University of Pennsylvania, Philadelphia; Phuong L. Mai, Magee-Women's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Heather Spencer Feigelson, Kaiser Permanente Institute for Health Research, Denver, CO; Mia M. Gaudet, American Cancer Society, Atlanta, GA; Karen Hurley and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mark E. Robson, Weill Cornell Medical College, New York, NY; Felicitas Lacbawan, Quest Diagnostics Nichols Institute, San Juan Capistrano; Thomas P. Slavin, City of Hope, Duarte, CA; Evan R. Myers, Duke University Medical Center, Durham, NC; Lisa F. Rezende, FORCE: Facing Our Risk of Cancer Empowered, Tampa; Mark E. Sherman, Mayo Clinic, Jacksonville, FL; and Elizabeth M. Swisher, University of Washington Medical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501360PMC
July 2017

Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis.

Gynecol Oncol 2017 06 20;145(3):584-594. Epub 2017 Feb 20.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.02.026DOI Listing
June 2017

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

J Clin Oncol 2017 Apr 21;35(11):1240-1249. Epub 2017 Feb 21.

Stephanie Lheureux, Jeff P. Bruce, Julia V. Burnier, Katherine Karakasis, S.Y. Cindy Yang, Rene Quevedo, Tiantian Li, Mark Dowar, Valerie Bowering, Trevor J. Pugh, and Amit M. Oza, Princess Margaret Cancer Centre; Stephanie Lheureux, Patricia A. Shaw, Blaise A. Clarke, S.Y. Cindy Yang, Rene Quevedo, Trevor J. Pugh, and Amit M. Oza, University of Toronto; Patricia A. Shaw and Blaise A. Clarke, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3677DOI Listing
April 2017

Niraparib for the treatment of ovarian cancer.

Expert Opin Pharmacother 2017 Apr 7;18(6):631-640. Epub 2017 Apr 7.

a Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre , University of Toronto , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1297423DOI Listing
April 2017

Treatment strategies for endometrial cancer: current practice and perspective.

Curr Opin Obstet Gynecol 2017 02;29(1):47-58

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0000000000000338DOI Listing
February 2017

Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.

Am Soc Clin Oncol Educ Book 2016 ;35:e247-57

From the Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan; Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, Canada; Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Gynecology and Obstetrics, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158675DOI Listing
January 2017

Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

Eur J Cancer 2016 05 25;59:99-108. Epub 2016 Mar 25.

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.02.016DOI Listing
May 2016

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.

Front Oncol 2016 11;6:119. Epub 2016 May 11.

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862980PMC
May 2016

Ovarian cancer treatment: The end of empiricism?

Cancer 2015 Sep 10;121(18):3203-11. Epub 2015 Jun 10.

Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744728PMC
September 2015

Safety evaluation of olaparib for treating ovarian cancer.

Expert Opin Drug Saf 2015 Aug 8;14(8):1305-16. Epub 2015 Jun 8.

University of Toronto, Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Drug Development Program , 610 University Avenue, Toronto, Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2015.1045875DOI Listing
August 2015

Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.

Gynecol Oncol 2015 Aug 10;138(2):235-7. Epub 2015 Jun 10.

Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.06.014DOI Listing
August 2015

Targeting the microenvironment in ovarian cancer.

Lancet Oncol 2015 May 14;16(5):485-6. Epub 2015 Apr 14.

Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)70157-9DOI Listing
May 2015

Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.

Int J Cancer 2015 Mar 8;136(5):E340-50. Epub 2014 Aug 8.

Normandy University, Caen, France; UNICAEN, Unité "Biologie et Thérapies Innovantes des Cancers Localement Agressifs" (EA 4656), Centre de Lutte Contre le Cancer François Baclesse, 14076 Caen Cedex 05, France; Centre de Lutte Contre le Cancer François Baclesse, 3 Avenue du Général Harris, BP5026, 14076 Caen Cedex 05, France; Service de recherche clinique, Centre de Lutte Contre le Cancer François Baclesse, 14076 Caen Cedex 05, France; Comité d'Uro-gynécolgie Oncologique, Centre de Lutte Contre le Cancer François Baclesse, 14076 Caen Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29104DOI Listing
March 2015

Non-target progression--the fine line between objectivity and subjectivity.

Eur J Cancer 2014 Dec 18;50(18):3271-2. Epub 2014 Oct 18.

Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.08.021DOI Listing
December 2014

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

Cancer Lett 2014 Jun 18;348(1-2):38-49. Epub 2014 Mar 18.

Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.03.001DOI Listing
June 2014

Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.

Expert Opin Investig Drugs 2014 Jun 9;23(6):773-92. Epub 2014 Apr 9.

Princess Margaret Hospital, Division of Medical Oncology and Hematology , 610 University Avenue, Toronto, Ontario, M5G 2M9 , Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2014.907272DOI Listing
June 2014

F18-choline, a novel PET tracer for parathyroid adenoma?

J Clin Endocrinol Metab 2013 Aug 20;98(8):3111-2. Epub 2013 Jun 20.

Service de Médecine Nucléaire, Centre François Baclesse, Avenue Général Harris, 14076 Caen Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-2084DOI Listing
August 2013

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Apoptosis 2013 Apr;18(4):492-508

Unité Biologie et Thérapies Innovantes des Cancers Localement Agressifs (EA 4656, Université de Caen Basse-Normandie et SF 4206 ICORE), Centre de Lutte Contre le Cancer François Baclesse, 3 Avenue du Général Harris, BP 5026, 14076 Caen Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-012-0799-xDOI Listing
April 2013

[A rare case of a tumour with two components in a young patient with diagnosed Crohn's disease].

Ann Pathol 2013 Apr 19;33(2):122-4. Epub 2013 Mar 19.

Service d'oncologie médicale, centre François-Baclesse, avenue du Général-Harris, 14000 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annpat.2012.11.003DOI Listing
April 2013

Nanocarriers for the targeted treatment of ovarian cancers.

Biomaterials 2013 Jan 20;34(4):1073-101. Epub 2012 Nov 20.

Université de Caen Basse-Normandie, EA 4258 CERMN, FR CNRS 3038 INC3M, SF 4206 ICORE, UFR des Sciences Pharmaceutiques, F-14032 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2012.10.055DOI Listing
January 2013

The motivations and methodology for high-throughput PET imaging of small animals in cancer research.

Eur J Nucl Med Mol Imaging 2012 Sep 13;39(9):1497-509. Epub 2012 Jul 13.

Nuclear Medicine Department, François Baclesse Cancer Centre, Avenue Général Harris, 14076 Caen Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-012-2177-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411308PMC
September 2012

[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].

Bull Cancer 2012 Sep;99(9):875-80

CLCC François-Baclesse, service de recherche clinique, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2012.1617DOI Listing
September 2012

[Malakoplakia associated with a colonic adenocarcinoma].

Ann Pathol 2012 Aug 13;32(4):308-10. Epub 2012 Aug 13.

Service d'oncologie médicale, centre François-Baclesse, avenue du-Général-Harris, 14000 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annpat.2012.07.001DOI Listing
August 2012

[Anticancer drugs management in renal insufficiency patients].

Bull Cancer 2012 Mar;99(3):323-31

Hôpital de la Pitié-Salpêtrière, service ICAR, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1489DOI Listing
March 2012

[Molecules involved in apoptosis regulation as therapeutic targets in oncology].

Bull Cancer 2011 Oct;98(9):1029-36

CLCC François-Baclesse, service d'oncologie médicale, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1381DOI Listing
October 2011

Metastatic renal cancer: evolution of five complete response cases after the antiangiogenic discontinuation.

Bull Cancer 2011 Jun 9. Epub 2011 Jun 9.

CLCC François-Baclesse, service de recherche clinique, avenue du Général-Harris, 14000 Caen, FranceCLCC François-Baclesse, service de recherche clinique, avenue du Général-Harris, 14000 Caen, France.

View Article

Download full-text PDF

Source
http://www.john-libbey-eurotext.fr/medline.md?doi=10.1684/bd
Publisher Site
http://dx.doi.org/10.1684/bdc.2011.1368DOI Listing
June 2011

Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer.

Breast Cancer Res Treat 2011 Feb 17;125(3):885-91. Epub 2010 Sep 17.

Département de recherche clinique, Centre de lutte contre le Cancer François Baclesse, Avenue du Général Harris, 14000, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-1165-8DOI Listing
February 2011

Ivory vertebra appearing photopenic on Tc-99m MDP bone scan: demonstration by SPECT/CT.

Clin Nucl Med 2008 Jul;33(7):479-81

Nuclear Medicine Department, François Baclesse Comprehensive Cancer centre, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0b013e31817793e5DOI Listing
July 2008